The study found cost savings and improved health outcomes when CellerateRX was used as an adjunct to standard care for high-risk spinal surgery patients compared with standard care alone.

Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients.

"We are pleased to see the publication of this peer-reviewed study, which represents an important addition to the compelling body of clinical evidence supporting CellerateRX's value proposition in the management of surgical wounds," said Seth Yon, Sanara's President and Chief Executive Officer. "Its findings demonstrate the significant reductions in medical costs and improvements in health outcomes that can be achieved using CellerateRX to manage acute surgical wounds following spine surgery for high-risk patients. Sanara remains committed to bringing clinically effective, cost-saving solutions like CellerateRX to surgeons and their patients, and we look forward to raising awareness of this new publication in the marketplace."

The study's researchers utilized economic modeling to evaluate the clinical outcomes and direct medical costs of a cohort of high-comorbidity patients undergoing complex spinal surgery procedures. They classified patients into two treatment arms: 1) those treated with CellerateRX as an adjunct to the standard of care, and 2) those treated with the standard of care alone, for the management of acute surgical wounds following spine surgery.

Based on the published clinical literature for each treatment arm, researchers evaluated the incidence of post-operative complications, hospital readmissions and surgical revision procedures over a one-year time horizon. The clinical efficacy of each treatment arm over this period was measured in quality-adjusted life years ("QALYs"), while the direct medical costs were measured in 2025 U.S. dollars.

The researchers found that the group treated with CellerateRX exhibited a dominant cost-effectiveness profile compared to the group treated with the standard of care alone. Specifically, the CellerateRX treatment arm generated $3,852 in cost savings and a 0.007 QALY gain per patient, yielding a net monetary benefit of $4,542. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively. In a probabilistic analysis conducted as part of the study, the CellerateRX treatment arm was found to have the dominant cost-effectiveness profile compared to treatment with the standard of care alone in more than 99% of clinical variability simulations.

Based on these findings, the researchers concluded that CellerateRX can promote both improved health outcomes and cost savings compared to the standard of care alone for wound management in high-risk spinal surgery populations. They added that their findings support CellerateRX as a value-enhancing component of the spine surgery care pathway, particularly for patients with elevated complication risk.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478962659/2227/2026-05-11T22:37:46